AI Automated Translation.
theBio
-
Nobo Medicine gains clinical momentum ahead of IPO, targets new drug approval filing next year
Novomedison Company Overview / Graphic by Lee Ji-hye Novomedison is accelerating the commercialization of its lead pipeline, the blood cancer treatment "Poseltinib." The company aims to apply for dome...
-
DRTECH posts record Q3 revenue of 34.5 billion won, maintains operating profit
D-TECH’s C-arm ‘Extron 6 Omni’. /Photo provided by D-TECH D-TECH maintained its profitable structure while continuing to expand its business scale in the second half of this year. On the 13th, D-TECH...
-
SK Biopharm launches epilepsy drug cenobamate in Japan
Xenobamate /Photo=SK Biopharmaceuticals SK Biopharmaceuticals has launched its new epilepsy drug 'Xenobamate' in Japan. The company plans to strengthen its global position by expanding its presence in...
-
DRTECH's bendable detector approved for use by Saudi Aramco and ADNOC
A scene of installing Dialtech's bendable detector on a pipeline. /Photo provided by Dialtech Dialtech announced on the 13th that it has obtained final use procedure approval for its bendable (flexibl...
-
Samsung Biologics labor, management to resume talks next week as prolonged strike reaches turning point
/Photo=News1 Labor and management at Samsung Biologics Logistics, which have been in conflict over wage and collective bargaining agreements, are expected to resume negotiations next week. As the seco...
-
Boryung breaks ground on second anticancer drug production facility at Yesan campus
Attendees cut a commemorative ribbon at the "Boryeong Co., Ltd. Yeosu Campus Second Anticancer Injection Building Groundbreaking Ceremony" held on the 12th at the Yeosu Campus./Photo=Boryeong Boryeong...
-
Huons posts 4.5 billion won operating loss in Q3, citing strengthened R&D and US recall costs
Huons CI /Photo=Huons Huons recorded an operating loss of 4.5 billion won in the third quarter of this year, turning to a deficit compared with the same period last year. The company explained that th...
-
Lunit posts record Q3 revenue of 22.2 billion won, cuts operating loss by 50 percent year-on-year
Medical artificial intelligence (AI) company Lunit announced on the 12th that its third-quarter revenue reached 22.215 billion won on a consolidated basis, up 13% from the same period last year. The o...
-
IVIM Technology accelerates global sales of intravital microscopes, expects stronger earnings growth
iBeam Technology Company Overview / Graphic by Yoon Sun-jung iBeam Technology is accelerating the global supply of its self-developed intravital microscopy. The company signed multiple supply contract...
-
Biotech duo takes on immune drug development, targeting ingredients and finished products
Yoon Doo-won (left in photo) and Kang Gyu-seok, co-CEOs of Schmidt Healthcare Korea. /Photo=Schmidt Healthcare Korea 'Pharma-Bio Veterans' with extensive experience as project managers (PMs) at domest...
-
Aitrics denies claims its AI product violates government rules, cites regulatory approval and court rulings
/Photo=Provided by 8Tricks 8Tricks dismissed claims that its product is being used in violation of government notices, stating, "There is no basis for this in the text of the notice, the regulatory au...
-
Military bases and airports without pharmacies allowed to sell basic medicines
The government will improve regulations to allow the use of safe over-the-counter medicines, such as antipyretic analgesics and cold medicine, at military bases and airports that do not have a pharmac...
-
1.
“Drunk driving” actor Ko Kyung-pyo “deeply reflects”… Hangout with Yoo and ‘Bokeum Magical 2’ in crisis
-
2.
"Photo torn out and stomped on" — Jeon So-mi reveals enduring scars from school bullying
-
3.
Ha Ji-won's drunken dance revealed despite agency's request to cut it
-
4.
AI-Driven Shift in the Copper Foil Market: Full-Scale Price Hikes for Battery Foils Amid Supply Shortages?
-
5.
"Too much trauma"… Lee Hee-jin reveals why marriage scares her
in THEBIO
-
1.
Daewoong Pharm begins Phase 1 trial of gut lining regeneration drug, aims for best-in-class oral therapy
-
2.
CAR-T therapy Yescarta clears first reimbursement hurdle, drawing welcome from patient groups
-
3.
Nobo Medicine gains clinical momentum ahead of IPO, targets new drug approval filing next year
-
4.
Samsung Biologics labor, management to resume talks next week as prolonged strike reaches turning point
-
5.
Biotech duo takes on immune drug development, targeting ingredients and finished products